NASDAQ · QTTB
Q32 Bio Inc.
$8.71-$0.16 (-1.79%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.24% below the high.
Loading market information…
NASDAQ · AZRX · USD
Stock price, earnings
Quote as of Sep 22, 2021, 04:00 AM UTC. Cached market data; not a live quote.
Price history is currently unavailable.
AzurRx BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 5.74% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow AzurRx BioPharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101. MS1819 is an acid-stable lipase enzyme (LIP2), originating from Yarrowia lipolytica, which AzurRx is genetically engineering to address exocrine pancreatic insufficiency (EPI). EPI is a debilitating disorder often seen in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). The second promising compound, AZX1101, is a recombinant beta-lactamase combination sourced from bacteria. This asset is being engineered with a dual aim: to avert nosocomial infections caused by resistant bacterial strains, especially after intravenous beta-lactam antibiotic administration, and to mitigate antibiotic-associated diarrhea (AAD).
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:48 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2019 |
|---|
| Nov 14, 2019 |
| -$1.70-8.28% vs estimate |
| $0.00 |
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.71-$0.16 (-1.79%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.24% below the high.
$1.02+$0.01 (+0.99%)
Lisata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.88% below the high.
$0.03-$0.02 (-31.78%)
Gritstone bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.98% below the high.
$0.09-$0.00 (-1.32%)
Atreca, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.5% below the high.
$0.20+$0.10 (+92.77%)
Unity Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.55% below the high.
$0.00$0.00 (0.0%)
RVL Pharmaceuticals plc’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
$0.15-$0.01 (-5.96%)
VivoSim Labs, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.64% below the high.
$0.57-$0.02 (-3.05%)
Onconetix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.7% below the high.
